Plain-English translation of NCT06560801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether dapagliflozin, a medication that helps protect kidneys and the heart, can improve how well a transplanted kidney works. Researchers want to see if adding this medication to standard care helps keep transplanted kidneys healthier over time. The study will compare people who take the medication plus standard care to those who receive standard care alone.
After kidney transplantation, the new kidney can gradually lose function over time, which increases the risk of heart problems and death. This medication has shown promise in protecting kidneys in other patient groups, but researchers haven't yet tested whether it works specifically in people who have had a kidney transplant.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either take the medication plus your regular kidney transplant care, or to continue with your regular care alone. You will visit the study center multiple times over one year for blood tests, urine tests, blood pressure checks, and special imaging scans of your kidney to see how well the medication is working. The study team will monitor you closely to make sure the medication is safe for you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany